StevenWPipeMD
Pediatric Hematology & Oncology • Ann Arbor, MIPediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology
Professor, Pediatrics & Communicable Diseases, University of Michigan Medical School
Dr. Pipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
D4207 MPB
Ann Arbor, MI 48109Phone+1 734-232-9335Fax+1 734-615-0464
Education & Training
University of MichiganFellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
MI State Medical License 1996 - 2025- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Dose Confirmation Trial of AAV5-hFIXco-Padua Start of enrollment: 2018 Jul 24
- HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients Start of enrollment: 2018 Jun 27
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors Start of enrollment: 2019 Jan 30
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Experience with trametinib in a pediatric patient with MAP2K1-related cervicofacial arteriovenous malformation.Neeraja Swaminathan, Joshua D Smith, Hemant A Parmar, Joseph J Gemmete, Steven W Pipe
Pediatric Blood & Cancer. 2024-11-01 - A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.Cedric Hermans, Leonard A Valentino, Courtney D Thornburg, Carmen Unzu, Mark A Kay
Haemophilia. 2024-10-22 - 4 citationsHeterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.Einas Elsheikh, Michelle Lavin, Lilian Antunes Heck, Niamh Larkin, Brendan Mullaney
Journal of Thrombosis and Haemostasis. 2023-05-01
Abstracts/Posters
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BSteven Pipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- Gene Therapy Can Transform Life for People with Hemophilia. But Some Patients Don’t Want ItJanuary 29th, 2023
- Most Patients Bleed-Free at 3 Years After Roctavian in GENEr8-1 TrialJanuary 13th, 2023
- Hemgenix Gene Therapy Benefits Sustained for 2 Years in Phase 3 TrialDecember 14th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
